Eli Lilly and Company

NYSE:LLY

Drug Manufacturers - General

Healthcare
$1,382.54 -0.95%

-$10.54 today

Market cap
$1.30T
Beta
0.52
P/E (TTM)
39.0
EPS (TTM)
$28.26
Dividend yield
0.59%
52W Low $623.78High $1,182.73

Volume 2.58M

Average 3.19M

LLY Deferred Tax Liabilities

Taxes owed in future periods because of timing differences between accounting and tax rules.

Eli Lilly and CompanyNYSE: LLY

Deferred Tax Liabilities · Q2 FY2026 · quarter ended Jun 2026

Deferred tax liabilities remains negative

Q2 FY2026 deferred tax liabilities was $5.46B, compared with $0 a year earlier.

Context

  • Deferred tax liabilities amounted to 3.8% of total assets at the end of Q2 FY2026, up 3.8 pp from a year earlier.
  • Deferred tax liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$5.46B— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoJun 2025
$0— since
Deferred Tax Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Tax Liabilities history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Tax Liabilities vs competitors

How LLY compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred tax liabilities is compared through growth and share of total assets rather than absolute size.
  • Deferred tax liabilities amounts to 3.8% of total assets for LLY, versus a peer median of 1.4%.
LLY Competitors
Deferred Tax Liabilities for LLY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LLYEli Lilly and CompanyJun 2026$5.46B USD——3.8%
NVSNovartis AGJun 2026$5.29B USD+128.0%+44.0%4.3%
JNJJohnson & JohnsonSep 2026$4.84B USD-19.3%+19.4%2.4%
NVONovo Nordisk A/SJun 2026DKK 4.27B DKK-56.4%-2.2%0.7%
AZNAstraZeneca PLCSep 2026$3.61B USD+0.2%+6.0%3.0%
ABBVAbbVie Inc.Jun 2026$2.28B USD-10.8%-2.9%1.7%
PFEPfizer Inc.Jun 2026$1.96B USD-20.8%+32.9%1.0%
SNYSanofiJun 2026€1.55B EUR-9.4%-3.3%1.2%
MRKMerck & Co., Inc.Jun 2026$1.43B USD+0.4%-7.1%1.1%
AMGNAmgen Inc.Jun 2026$1.3B USD-6.1%+398.9%1.4%
Peer median (excluding LLY) —-9.4%+6.0%1.4%

Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents3.82B2.07B2.82B3.27B7.16B
Short-term Investments90.1M144.8M109.1M154.8M105M
Net Receivables8.13B8.56B11.34B13.28B20.16B
Inventory3.89B4.31B5.77B7.59B13.74B
Other Current Assets07.3M149.5M111.4M147M
Total Current Assets18.45B18.03B25.73B32.74B55.63B
Property, Plant & Equipment (Net)8.99B10.14B12.91B17.1B24.68B
Goodwill3.89B4.07B4.94B5.77B5.9B
Intangible Assets7.69B7.21B6.91B6.17B6.52B
Long-term Investments3.21B2.9B3.05B3.22B2.8B
Tax Assets2.49B2.79B5.48B8B9.96B
Other Non-current Assets4.08B4.34B4.99B5.72B6.99B
Total Non-current Assets30.35B31.46B38.28B45.98B56.85B
Total Assets48.81B49.49B64.01B78.71B112.48B
Account Payables1.67B1.93B2.6B3.23B5.38B
Short-term Debt1.54B1.5B6.9B5.12B1.64B
Tax Payables126.9M475.1M3.85B05.88B
Deferred Revenue00000
Other Current Liabilities10.68B3.91B4.93B7.15B28.21B
Total Current Liabilities15.05B17.14B27.29B28.38B35.23B
Long-term Debt15.35B14.74B18.32B28.53B40.87B
Deferred Tax Liabilities1.73B87.3M000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities7.52B6.75B7.53B7.54B9.85B
Total Non-current Liabilities24.6B21.58B25.85B36.07B50.71B
Total Liabilities39.65B38.71B53.14B64.44B85.94B
Common Stock596.3M594.1M593.6M592.4M590M
Retained Earnings8.96B10.04B10.31B13.55B24.47B
Accumulated OCI(4.34B)(3.84B)(4.33B)(4.32B)(2.88B)
Other Stockholders Equity(3.01B)(3.01B)(3.01B)(3.01B)(2.99B)
Minority Interest175.6M125.6M91.8M79.5M0
Total Equity9.15B10.78B10.86B14.27B26.54B
Total Debt16.88B16.24B25.23B33.64B42.5B
Net Debt13.07B14.17B22.41B30.38B35.34B

Eli Lilly and Company

NYSE:LLY

Intrinsic Alpha fair value

Locked

Current Price

$1,382.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.